HEMLIBRA for subcutaneous injection 105mg (ヘムライブラ皮下注105mg)

País: Japón

Idioma: inglés

Fuente: すりの適正使用協議会 RAD-AR Council, Japan

Ingredientes activos:

Emicizumab(genetical recombination)

Disponible desde:

Chugai Pharmaceutical Co., Ltd.

Designación común internacional (DCI):

Emicizumab(genetical recombination)

formulario farmacéutico:

injection

Información para el usuario

Drug Information Sheet("Kusuri-no-Shiori")
Self-injection
Revised: 06/2022
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
HEMLIBRA FOR SUBCUTANEOUS INJECTION 105MG
ACTIVE INGREDIENT:
Emicizumab(genetical recombination)
DOSAGE FORM:
injection
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine improves the symptom of prolonged bleeding by promoting
the activation of
blood-clotting protein in the blood.
It is usually used to suppress a bleeding tendency in patients with
congenital hemophilia
A(congenital blood coagulation factor VIII deficiency) and acquired
hemophilia A.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
・If you are pregnant or breastfeeding.
・If you are taking any other medicinal products. (Some medicines may
interact to enhance or
diminish medicinal effects. Beware of over-the-counter medicines and
dietary supplements
as well as other prescription medicines.)
DOSING SCHEDULE (HOW TO TAKE THIS MEDICINE)
・
Your dosing schedule prescribed by your doctor is((         

to be written by a healthcare
professional
))
・Congenital hemophilia A : In general, subcutaneously inject 3 mg of
the active ingredient
per kilogram of the body weight (mg/kg), at an interval of 1 week for
4 times, then
subcutaneously inject according to any one of the following dosing
schedule. Strictly follow
the instructions.
- 1.5 mg/kg, at an interval of 1 week.
- 3 mg/kg, at an interval of 2 weeks.
- 6 mg/kg, at an interval of 4 weeks.
Acquired h